We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $1.7B
1-Year Est. Return 93.03%
This Fund
S&P 500
This Quarter Est. Return
-7.42%
1 Year Est. Return
+93.03%
3 Year Est. Return
+228.43%
5 Year Est. Return
+368.14%
10 Year Est. Return
+4,607.77%
AUM
$3.97B
AUM Growth
-$356M
Cap. Flow
+$116M
Cap. Flow %
2.92%
Top 10 Hldgs %
30.63%
Holding
140
New
5
Increased
76
Reduced
8
Closed
5

Top Buys

Rank Stock Value
1
AMLX icon
Amylyx Pharmaceuticals
AMLX
+$22.5M
2
CINC
CinCor Pharma, Inc. Common Stock
CINC
+$21.2M
3
DXCM icon
DexCom
DXCM
+$20.7M
4
IDXX icon
Idexx Laboratories
IDXX
+$20.4M
5
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$15.3M

Top Sells

Rank Stock Value
1
HCA icon
HCA Healthcare
HCA
+$18.8M
2
ISRG icon
Intuitive Surgical
ISRG
+$18M
3
IMRX icon
Immuneering
IMRX
+$17.6M
4
WHWK
Whitehawk Therapeutics
WHWK
+$13M
5
VERV
Verve Therapeutics
VERV
+$11.4M

Sector Composition

Rank Sector Weight
1 Healthcare 95.08%
2 Consumer Staples 1.53%
3 Industrials 0.67%
4 Financials 0.29%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
VERV
76
DELISTED
Verve Therapeutics
VERV
$11.5M 0.29%
504,037
-398,889
-44% -$11.4M
KDNY
77
DELISTED
Chinook Therapeutics, Inc. Common Stock
KDNY
$11.5M 0.29%
700,349
-20,000
-3% -$272K
AMYT
78
DELISTED
Amryt Pharma plc American Depositary Shares
AMYT
$10.8M 0.27%
1,305,825
– –
FULC icon
79
Fulcrum Therapeutics
FULC
$285M
$10.3M 0.26%
434,590
-22,400
-5% -$317K
OHPAU
80
DELISTED
Orion Acquisition Corp. Unit
OHPAU
$9.82M 0.25%
1,000,000
– –
FOLD
81
DELISTED
Amicus Therapeutics
FOLD
$9.59M 0.24%
1,012,506
– –
AUPH icon
82
Aurinia Pharmaceuticals
AUPH
$2.06B
$9.54M 0.24%
771,018
+313,845
+69% +$4.85M
LENZ
83
LENZ Therapeutics
LENZ
$166M
$9.13M 0.23%
255,822
-41,165
-14% -$2.58M
AKRO
84
DELISTED
Akero Therapeutics
AKRO
$9.01M 0.23%
635,214
+48,113
+8% +$842K
GMDA
85
DELISTED
Gamida Cell Ltd. Ordinary Shares
GMDA
$8.94M 0.23%
2,154,300
– –
SPRO icon
86
Spero Therapeutics
SPRO
$70.6M
$8.62M 0.22%
990,913
+45,600
+5% +$467K
XLO icon
87
Xilio Therapeutics
XLO
$59.4M
$8.42M 0.21%
85,078
– –
EPZM
88
DELISTED
Epizyme, Inc
EPZM
$8.36M 0.21%
7,267,696
+3,460,034
+91% +$5.64M
MGNX icon
89
MacroGenics
MGNX
$252M
$8.22M 0.21%
932,728
+75,523
+9% +$834K
LONA
90
LeonaBio Inc
LONA
$71.4M
$7.46M 0.19%
55,225
– –
FUSN
91
DELISTED
Fusion Pharmaceuticals Inc. Common Shares
FUSN
$7.37M 0.19%
948,327
– –
CMPX icon
92
Compass Therapeutics
CMPX
$412M
$7.3M 0.18%
5,328,088
– –
CGEM icon
93
Cullinan Oncology
CGEM
$1.24B
$6.83M 0.17%
652,578
+6,500
+1% +$87.8K
MREO
94
Mereo BioPharma
MREO
$55.9M
$6.8M 0.17%
6,074,943
+489,322
+9% +$633K
CYPH
95
Cypherpunk Technologies Inc
CYPH
$71.7M
$6.29M 0.16%
359,545
+7,488
+2% +$160K
FOCL
96
EDAP TMS S.A.
FOCL
$233M
$5.95M 0.15%
820,000
+59,100
+8% +$417K
NKTX icon
97
Nkarta
NKTX
$163M
$5.8M 0.15%
509,948
+2,700
+0.5% +$28.9K
DSGN icon
98
Design Therapeutics
DSGN
$907M
$5.58M 0.14%
345,597
+10,350
+3% +$159K
ICVX
99
DELISTED
Icosavax, Inc. Common Stock
ICVX
$5.36M 0.13%
761,557
+26,053
+4% +$410K
BMEA icon
100
Biomea Fusion
BMEA
$94.2M
$5.2M 0.13%
1,165,582
– –
2 3
4
5 6

Similar funds

ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
BCM
BlueCrest Capital Management St Helier, Jersey $1.69B AUM 20.01% 1-Year Est. Return
PP
PDT Partners New York $1.69B AUM 74.01% 1-Year Est. Return
GAM
Goldentree Asset Management New York $1.69B AUM 10.69% 1-Year Est. Return
FACM
Forest Avenue Capital Management Miami, Florida $1.69B AUM 104.84% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $1.68B AUM 40.61% 1-Year Est. Return
JIP
Jaffetilchin Investment Partners Tampa, Florida $1.68B AUM 22.81% 1-Year Est. Return
II
Inspire Investing Meridian, Idaho $1.71B AUM 31.76% 1-Year Est. Return

Rock Springs Capital Management's Q1 2022 Portfolio in Review

As of Q1 2022, Rock Springs Capital Management held 140 positions worth $3.97B, down 8.2% from $4.33B the previous quarter. Its ten largest holdings account for 31% of the portfolio.

Rock Springs Capital Management's Q1 2022 filing shows 5 new, 76 increased, 8 reduced and 5 closed positions. Its largest new stake was Amylyx Pharmaceuticals: 998,307 shares worth $12.8M. The largest sale was HCA Healthcare, an estimated $18.8M.

By sector, the portfolio is most concentrated in Healthcare at 95% of assets, up from 94% a quarter earlier, followed by Consumer Staples and Industrials.

  • Rock Springs Capital Management's largest Q1 2022 buy was Amylyx Pharmaceuticals: 998,307 shares worth $12.8M.
  • Rock Springs Capital Management added most to DexCom in Q1 2022, an estimated $20.7M increase.
  • Rock Springs Capital Management's biggest Q1 2022 reduction was HCA Healthcare, cutting an estimated $18.8M.
  • Rock Springs Capital Management fully exited Immuneering in Q1 2022, selling an estimated $17.6M.
  • Rock Springs Capital Management's ten largest holdings make up 31% of its $3.97B portfolio in Q1 2022.
  • Rock Springs Capital Management opened 5 new positions and closed 5 in Q1 2022.
  • Rock Springs Capital Management's portfolio value fell 8.2% quarter-over-quarter to $3.97B.

Based on Rock Springs Capital Management's 13F filing for Q1 2022, filed 16 May 2022.